Navigation Links
Quanterix Appoints Paul Chapman as President and Chief Executive Officer
Date:7/20/2012

LEXINGTON, Mass., July 20, 2012 /PRNewswire/ -- Quanterix Corporation, developer of the Single Molecule Array (Simoa) technology, announced today that it has appointed Paul Chapman as its new President and Chief Executive Officer.  Mr. Chapman joins the company at a pivotal time, as it moves from development to commercialization of its revolutionary digital ELISA platform that improves conventional immunoassay sensitivity 1000-fold.

"Quanterix's Simoa technology has the potential to dramatically change the world of biomarker research and clinical diagnostics," says Chapman.   "I am very excited to work with the exceptional team at Quanterix to make that potential a reality in the near future."

Prior to joining Quanterix, Mr. Chapman was Vice President of the BioPharm Process Solutions business at EMD Millipore where he was responsible for the Marketing and R&D teams in the $800 million business.   Prior to joining Millipore, he was the Vice President, Hospital Solutions for Roche Near Patient Testing in Austria, where he held P&L responsibility for Roche's decentralized Cardiac, Blood Gas / Electrolyte and Hospital Glucose businesses.  Mr. Chapman was also the International Business Development Manager at Roche Molecular Diagnostics for blood screening and, prior to that, held an array of sales and marketing positions at Roche Diagnostics Canada (where he began his career in 1993) focused primarily in the Molecular Diagnostics field.  Mr Chapman has a B.Sc. in Microbiology from the University of Western Ontario, a B.Sc (hons) in Immunology from the University of Guelph Ontario, and graduated from the Marketing Management Program (MMP) from the Richard Ivy School of Business.

"Paul is a visionary leader with a strong track record in several businesses and I have great confidence that he will make Quanterix a huge success," says Martin Madaus, Executive Chairman of the Board of Directors. "His background and capabilities to bring new technologies to market successfully make him uniquely qualified for Quanterix."  

Dr. Martin Madaus, who was previously CEO and Executive Chairman of the Board of Directors, will continue at Quanterix as the Executive Chairman, while Mr. Chapman takes the reins of the company's operations as President and Chief Executive Officer to prepare the organization for the launch of its first product in 2013. 

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
2. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
3. C3i Appoints Jonathan Song to Business Development Executive in Asia
4. Organovo Holdings Appoints James T. Glover to Board of Directors
5. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
6. ReShape Medical Appoints Robert E. Grant to Board of Directors
7. Nile Therapeutics Appoints Darlene Horton, M.D., as Chief Medical Officer
8. Stereotaxis Appoints William C. Mills III as Chairman of Board of Directors
9. Gentech Pharmaceutical Appoints New Medical Director for PhenTabz/ADDTabz
10. GenVec Appoints Cynthia Collins as President and CEO
11. Accuray Appoints Richard Pettingill, LFACHE to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
(Date:3/23/2017)... 23, 2017 The key factors driving ... diabetic population, accelerating economic growth and increasing healthcare expenditure. Some ... higher life expectancy of ESRD patients, rising demand for home ... the expansion of the market is hindered by high treatment ... ...
(Date:3/23/2017)... 23, 2017 As a result of ... the prevalence of allergic diseases, cutting edge developments ... revolutionising the ways in which pharmaceutical and biotech ... promises to be both a high quality meeting ... interest groups, immunologists, research scholars and doctors. The ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... Digital Scientists, a software innovation lab specializing in web design and ... Carolina location. The lab has set up shop at the renowned NEXT Innovation ... Carolina clients for years from our office here in Atlanta,” explains Digital Scientists’ CEO, ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... CA (PRWEB) , ... March 24, 2017 , ... ... on two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, ... Creating the Administrative Record, The majority of cases litigated under ERISA involve claims ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
Breaking Medicine News(10 mins):